Author

P. Gilchuk

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 12 Microbiology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 11 Research Focus:host-pathogen & immune response· 9 Organism:human· 9 Assay:proteomics· 7 Research Focus:drug response / drug discovery· 4 Research Focus:cell type annotation· 3 Approach:deep learning· 3 Approach:statistical model· 3

Frequent Co-Authors

J. E. Crowe· 14 shared R. H. Carnahan· 11 shared S. J. Zost· 8 shared E. Binshtein· 7 shared N. Suryadevara· 7 shared R. E. Sutton· 7 shared E. C. Chen· 6 shared R. S. Nargi· 6 shared

Activity by Year

2020-2022 · peak 7/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

14 shared papersImmunology

J. E. Crowe

Mutual co-authors in cluster

Author profile →

14 papers

Recent·Most cited

Systematic analysis of human antibody response to ebolavirus glycoprotein reveals high prevalence of neutralizing public clonotypes

E. C. Chen, P. Gilchuk, S. J. Zost, P. A. Ilinykh, E. Binshtein, K. Huang, L. Myers, S. Bonissone, S. Day, C. R. Kona, A. Trivette, J. X. Reidy, R. E. Sutton, C. Gainza, S. Monroig, , J. E. Crowe

The paper analyzes the human antibody response to ebolavirus glycoprotein, identifying public clonotypes with neutralizing activity and implications for vaccine design.

bioRxiv · Jan 12, 2022 · PreprintImmunology

A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in rhesus macaques

R. R. Cobb, J. Nkolola, P. Gilchuk, A. Chandrashekar, R. V. House, C. G. Earnhart, N. M. Dorsey, S. A. Hopkins, D. M. Snow, R. E. Chen, L. A. VanBlargan, M. Hechenblaickner, B. Hoppe, L. Collins, M. T. Tomic, , J. E. Crowe

This study shows that a combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in rhesus macaques and neutralizes variants of concern in vitro.

bioRxiv · Sep 27, 2021 · PreprintImmunology

Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals

E. C. Chen, P. Gilchuk, S. J. Zost, N. Suryadevara, E. S. Winkler, C. R. Cabel, E. Binshtein, R. E. Sutton, J. L. Rodriguez, S. Day, L. Myers, A. Trivette, J. K. Williams, E. Davidson, S. Li, , J. E. Crowe

The paper identifies public antibody clonotypes in SARS-CoV-2 convalescents and vaccinated individuals, revealing common epitope recognition and potential vaccine efficacy mechanisms.

bioRxiv · May 2, 2021Immunology

Protective pan-ebolavirus combination therapy by two multifunctional human antibodies

P. Gilchuk, C. D. Murin, R. W. Cross, P. A. Ilinykh, K. Huang, N. Kuzmina, V. Borisevich, K. N. Agans, J. B. Geisbert, R. H. Carnahan, R. S. Nargi, R. E. Sutton, N. Suryadevara, S. J. Zost, R. G. Bombardi, , J. E. Crowe

This paper develops a therapeutic cocktail of two human antibodies that protect against multiple ebolaviruses in non-human primates and reveals their molecular mechanisms.

bioRxiv · May 2, 2021 · PreprintImmunology

A potently neutralizing anti-SARS-CoV-2 antibody inhibits variants of concern by binding a highly conserved epitope

L. VanBlargan, L. Adams, Z. Liu, R. E. Chen, P. Gilchuk, S. Raju, B. Smith, H. Zhao, J. B. Case, E. S. Winkler, B. Whitener, L. Droit, I. Aziati, P.-Y. Shi, A. Creanga, , M. Diamond

The paper identifies an antibody that neutralizes all SARS-CoV-2 variants by targeting a conserved epitope on the spike protein.

bioRxiv · Apr 26, 2021Microbiology

Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail

J. Dong, S. Zost, A. Greaney, T. N. Starr, A. S. Dingens, E. C. Chen, R. Chen, B. Case, R. Sutton, P. Gilchuk, J. Rodriguez, E. Armstrong, C. Gainza, R. Nargi, E. Binshtein, , J. E. Crowe

This paper determines the structures of two antibodies in the AZD7442 cocktail that neutralize SARS-CoV-2 and identifies critical residues for neutralization and viral escape.

bioRxiv · Jan 27, 2021 · PreprintImmunology

Neutralizing and protective human monoclonal antibodies recognizing the N-terminaldomain of the SARS-CoV-2 spike protein

N. Suryadevara, S. Shrihari, P. Gilchuk, L. VanBlargan, E. Binshtein, S. Zost, R. Nargi, R. Sutton, E. S. Winkler, E. C. Chen, M. E. Fouch, E. Davidson, B. Doranz, R. H. Carnahan, L. Thackray, , J. E. Crowe

The paper identifies two NTD-specific human mAbs with neutralizing activity against SARS-CoV-2 and shows they require Fc effector functions for optimal protection.

bioRxiv · Jan 19, 2021Immunology

Canonical features of human antibodies recognizing the influenza hemagglutinin trimer interface

S. J. Zost, J. Dong, I. M. Gilchuk, P. Gilchuk, N. J. Thornburg, S. Bangaru, N. Kose, J. A. Finn, R. Bombardi, C. Soto, R. S. Nargi, R. P. Irving, N. Suryadevara, J. B. Westover, R. H. Carnahan, , J. E. Crowe

The paper identifies common genetic and structural features of human antibodies recognizing the influenza HA trimer interface, suggesting it as a target for vaccine design.

bioRxiv · Dec 31, 2020Immunology

Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions and monocytes for optimal therapeutic protection

E. S. Winkler, P. Gilchuk, J. Yu, A. L. Bailey, R. E. Chen, S. J. Zost, H. Jang, Y. Huang, J. D. Allen, J. B. Case, R. E. Sutton, R. H. Carnahan, T. L. Darling, A. C. M. Boon, M. Mack, , M. Diamond

This study shows that neutralizing antibodies against SARS-CoV-2 need intact Fc functions and monocytes for optimal therapeutic protection in animal models.

bioRxiv · Dec 28, 2020Immunology

Convergence of a common solution to broad ebolavirus neutralization by glycan cap directed human antibodies

C. D. Murin, P. Gilchuk, P. Ilinykh, K. Huang, N. Kuzmina, X. Shen, J. F. Brunh, A. L. Brunh, E. Davidson, B. Doranz, L. E. Williamson, J. Copps, T. Alkutkar, A. I. Flyak, A. Bukreyev, , A. B. Ward

The paper presents cryo-EM structures of glycan cap antibodies that neutralize ebolavirus by targeting a conserved MLD-anchor site, revealing common features among broadly neutralizing antibodies.

bioRxiv · Oct 14, 2020Immunology

Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition

A. J. Greaney, T. N. Starr, P. Gilchuk, S. J. Zost, E. Binshtein, A. N. Loes, S. K. Hilton, J. Huddleston, R. Eguia, K. H. Crawford, A. S. Dingens, R. S. Nargi, R. E. Sutton, N. Suryadevara, P. W. Rothlauf, , J. D. Bloom

This study maps mutations in the SARS-CoV-2 spike RBD that escape antibody recognition, revealing escape mutation patterns and enabling the design of antibody cocktails.

bioRxiv · Sep 10, 2020Microbiology

Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals

S. J. Zost, P. Gilchuk, J. B. Case, E. Binshtein, R. E. Chen, J. X. Reidy, A. Trivette, R. S. Nargi, R. E. Sutton, N. Suryadevara, L. E. Williamson, E. C. Chen, T. Jones, S. Day, L. Myers, , J. E. Crowe

The paper identifies potent neutralizing antibodies against SARS-CoV-2 that block receptor binding and protect animals, providing insights for vaccine and therapy development.

bioRxiv · May 22, 2020Immunology

Integrated technology platform for accelerated discovery of antiviral antibody therapeutics

P. Gilchuk, R. G. Bombardi, J. H. Erasmus, Q. Tan, R. S. Nargi, C. Soto, P. Abbink, T. J. Suscovich, L. A. Dunellin, A. Khandhar, J. Archer, J. Liang, M. E. Fouch, E. Davidson, B. Doranz, , R. H. Carnahan

This study develops an integrated platform to rapidly discover and validate potent antiviral human monoclonal antibodies against Zika virus.

bioRxiv · May 12, 2020Immunology

Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein

S. J. Zost, P. Gilchuk, R. Chen, J. B. Case, J. X. Reidy, A. Trivette, R. S. Nargi, R. E. Sutton, N. Suryadevara, E. C. Chen, E. Binshtein, S. Shrihari, M. A. Ostrowski, H. Y. Chu, J. E. Didier, , J. E. Crowe

This study isolates and profiles human monoclonal antibodies against SARS-CoV-2 spike protein, identifying neutralizing antibodies targeting the receptor-binding domain.

bioRxiv · May 12, 2020Immunology